Healthcare Triangle is trading at $4.10, down 11.26% in pre-market ahead of its scheduled November 5 Nasdaq delisting appeal hearing. - The hearing follows a delisting determination for failing the minimum-bid-price requirement; its outcome could affect continued listing. - The shares also fell 11.83% on November 4, extending recent weakness. - Positive supplied sector context for software does not explain the decline; pre-market volume data was unavailable. No result or new company announcement confirming the cause was found.